Simoa® Accelerator Laboratory

 
On

Simoa® Accelerator Laboratory

GREATER DEPTHS OF CONTRACT RESEARCH AT YOUR REACH

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The Simoa® Accelerator Laboratory is your go-to, CLIA-Licensed resource for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. Gain instant access to Quanterix’ full suite of instruments and assays including the new next-generation Simoa planar platform with 10-plex assay capability. Propel your research further than any other contract research company by detecting proteins and nucleic acids at the lowest possible levels with Simoa capabilities.

 

 

The Simoa Accelerator Laboratory:

  • State-of-the-art facility includes a CLIA-certified lab and puts the power of groundbreaking Simoa Technology to work to achieve research objectives
  • Offers the technology for single-plex and multiplex detection of proteins and nucleic acids, at ultra-sensitive levels
  • Provides the ability to use your proprietary antibodies/reagents or one of our extensive range of commercially-available assays
  • Infrastructure allows scalability to handle sample sets from one plate to thousands of samples
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope 
  • Onsite assay development training available through a comprehensive, 4-day program

Leverage Simoa for PK/PD, Efficacy, Safety and Target Engagement with the Highest Possible Sensitivity.

Quanterix’ team of dedicated scientists offer the greatest depth of instrument experience and ultra-sensitive assay development - all the way through manufacturing - giving you instant access to Simoa technology.  From expert and rapid development of custom assay kits, to selection of best antibody pairs, to running sample sets of any size, The Simoa Accelerator Lab treats every project with individualized attention to help your organization achieve its research and development goals efficiently and cost-effectively.

ALREADY WORKING WITH OUR ACCELERATOR TEAM?

Request to Learn More

Simoa Accelerator Leadership Team

Mark Roskey, Ph.D.
Senior Vice President, Commercial & Assays

Mark joined Quanterix in mid 2014 as the Vice President and General Manager of Applications and Reagents. He has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. He comes to Quanterix from PerkinElmer’s LST division where he was VP/GM of the America's Sales and Service organization. Prior to PerkinElmer, Mark held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011. Mark holds a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.

Mary Ellen Cortizas, JD
Vice President, CRO and Laboratory Services

Mary Ellen developed her operational expertise over a 30-year career at Boston Children’s Hospital. As Administrative Director of the Department of Laboratory Medicine, Mary Ellen had operational responsibility for clinical chemistry, hematology, microbiology, blood bank and molecular diagnostics.  In addition to laboratory roles, Mary Ellen had active roles in enterprise wide information technology, quality and regulatory management, emergency management, and strategic planning.  

Prior to joining Quanterix, Mary Ellen was a founder and Chief Operating Officer at Claritas Genomics, a molecular genomics company dedicated to advancing precision care for pediatric rare disease.  Claritas became the first clinical molecular diagnostic laboratory to achieve both ISO 15189 and New York State licensure for its unique exome-based diagnostics.  Mary Ellen oversaw successful execution of a $9 million grant to sequence 20,000 exomes for the Veteran Adminstration's Million Veterans project.

Mary Ellen has served on American Society of Clinical Pathologist Board of Registry exam committees, and is currently on the boards of two not-for profit organizations focused on youth development.

Mary Ellen graduated from Suffolk Law School and holds a BA in Biology from Tufts University. 

David Hanlon, Ph.D.
Vice President, Strategic Collaborations

Dr. Hanlon joined Quanterix in 2008 and oversees the Accelerator Laboratory, a service business dedicated to clinical sample testing and the development of novel assays utilizing the company’s single molecule array (Simoa) technology. Since its launch in 2014, the lab has expanded its capabilities to enable testing of up to 4,000 samples per day, and has completed over 770 projects from 223 organizations around the world. Prior to Quanterix, Dr. Hanlon led several external research collaborations at Cytyc (Hologic) to discover novel biomarkers of cervical neoplasia, as well as an internal team focused on marker validation and the development of diagnostic assays. Dr. Hanlon was Director, R&D at VisEn Medical and Project Manager at Proteome (Incyte), where he led a team of scientists developing protein-centric databases for comparative and functional genomic applications. He also served as Director of Neuroscience at Oncogene Research Products where he developed a life science portfolio consisting of neurochemical and immunological products. Dr. Hanlon received his Ph.D. from the University of Illinois, Urbana-Champaign and was a postdoctoral research fellow at Harvard University and the University of California, San Diego. He obtained a B.S. degree in Biochemistry from Worcester Polytechnic Institute.

Simoa Accelerator Lab by the Numbers

Customers to Date
Projects to Date
Samples Run to Date

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more